```html

Zoster‑Associated Facial Palsy

Overview

Zoster‑associated facial palsy, also known as herpes zoster oticus or Ramsay Hunt syndrome type 1, occurs when the varicella‑zoster virus (VZV) that causes chickenpox reactivates in the cranial nerve VII (the facial nerve) and surrounding structures. The result is an acute, often painful, unilateral facial paralysis that can range from mild weakness to complete loss of facial movement.

The condition most commonly affects adults over the age of 50, but it can occur at any age, especially in individuals with weakened immunity. Epidemiologic data from the CDC estimate that 10–20 % of all cases of peripheral facial palsy (Bell’s palsy) are attributable to VZV reactivation [1]. In a population‑based study from the United Kingdom, the incidence of Ramsay Hunt syndrome was ~12 cases per 1 million person‑years, with a higher rate in those aged ≥60 years [2].

Symptoms

Symptoms usually develop abruptly over several days and typically involve the same side of the face as the viral reactivation. A complete list includes:

• Facial weakness or paralysis – inability to raise the eyebrow, close the eye, smile, or puff out the cheek on the affected side.
• Otalgia (ear pain) – often severe and precedes the facial weakness.
• Vesicular eruption – painful, fluid‑filled blisters on the external ear (pinna), ear canal, or oral mucosa (hard palate, tongue, or gums). This is the hallmark “herpes zoster oticus” rash.
• Hearing loss – ranging from mild sensorineural loss to sudden profound deafness.
• Tinnitus – ringing or buzzing in the ear.
• Vertigo or disequilibrium – due to involvement of the vestibular portion of the eighth cranial nerve.
• Dry mouth or altered taste – because the chorda tympani (a branch of VII) carries taste fibers from the anterior two‑thirds of the tongue.
• Hyperacusis – increased sensitivity to sound because the stapedius muscle (innervated by VII) cannot dampen loud noises.
• Eye irritation – inability to close the eye leads to dryness, tearing, and risk of corneal ulceration.
• Facial pain or dysesthesia – abnormal sensations such as burning, tingling, or numbness.
• Post‑auricular lymphadenopathy – swollen lymph nodes behind the ear.

Symptoms usually peak within 48 hours and may improve over weeks, but up to 30 % of patients retain some degree of residual weakness or synkinesis (involuntary muscle movements) if treatment is delayed [3].

Causes and Risk Factors

What Causes Zoster‑Associated Facial Palsy?

The underlying cause is reactivation of latent VZV within the geniculate ganglion of the facial nerve. After primary infection (chickenpox), VZV remains dormant in dorsal root and cranial nerve ganglia. Stressors that impair cell‑mediated immunity—such as aging, immunosuppressive drugs, HIV infection, or malignancy—can trigger viral replication and spread along the facial nerve, leading to inflammation, edema, and ischemia of the nerve fibers.

Risk Factors

• Age ≥ 50 years – immune senescence increases reactivation risk.
• Immunocompromised state – organ transplant recipients, chemotherapy, long‑term corticosteroids, HIV/AIDS.
• History of chickenpox – virtually everyone born before 1995 has had primary VZV infection.
• Previous herpes zoster infection – especially in the ear or head region.
• Diabetes mellitus – associated with peripheral nerve vulnerability.
• Stress, trauma, or recent surgery – can transiently depress immunity.
• Smoking – linked to poorer outcomes after facial palsy.

Diagnosis

Prompt recognition is essential because antiviral therapy is most effective when started within 72 hours of symptom onset.

Clinical Evaluation

• History – onset of ear pain, rash, facial weakness, hearing changes.
• Physical examination – assessment of facial nerve grades (House‑Brackmann scale), otoscopic inspection for vesicles, audiometry, and vestibular testing if vertigo is present.

Laboratory and Imaging Studies

• Polymerase chain reaction (PCR) of vesicular fluid or saliva – detects VZV DNA with >95 % specificity [4].
• Serology – VZV IgM/IgG levels can support diagnosis but are less definitive.
• Magnetic resonance imaging (MRI) with contrast – shows enhancement of the facial nerve at the geniculate ganglion, helping differentiate from other causes (e.g., tumor, stroke).
• Electroneurography (ENoG) or EMG – performed 3–21 days after onset to quantify nerve degeneration and predict recovery.
• Audiogram & vestibular tests – baseline hearing assessment and evaluation of balance function.

Treatment Options

Therapy combines antiviral medication, corticosteroids, and supportive care. Early initiation dramatically improves recovery rates.

Antiviral Therapy

• Acyclovir 800 mg five times daily for 7–10 days.
• Valacyclovir 1 g three times daily for 7 days (more convenient dosing).
• Famciclovir 500 mg three times daily for 7 days.

Studies show that antivirals reduce the risk of long‑term facial weakness by ~30 % when started within 72 hours [5].

Corticosteroids

Prednisone 60 mg daily (or equivalent) for 5 days followed by a taper over 10 days is the most widely used regimen. Steroids diminish nerve edema and improve functional outcomes, especially when combined with antivirals.

Adjunctive Therapies

• Eye protection – lubricating drops, ointments, and an eye patch at night to prevent corneal drying.
• Physical therapy – facial exercises, biofeedback, and mirror therapy to retrain muscles and reduce synkinesis.
• Analgesia – acetaminophen or NSAIDs for pain; gabapentin for neuropathic pain if needed.
• Antiemetics & vestibular suppressants – for severe vertigo (e.g., meclizine).

Surgical and Procedural Options

Most patients improve with medical therapy. Surgical decompression of the facial nerve is reserved for:

• Rapidly progressive paralysis with >90 % degeneration on ENoG within 2 weeks.
• Failure to improve after 3–4 months of optimal medical treatment.

Procedures include facial nerve decompression via mastoidectomy or endoscopic approaches, performed by an otolaryngologist or neuro‑otologist.

Lifestyle and Home Measures

• Maintain good hydration and nutrition to support immune recovery.
• Avoid smoking and limit alcohol, which can impair nerve healing.
• Apply cool compresses to the ear for pain relief (15 min, several times daily).

Living with Zoster‑Associated Facial Palsy

Daily Management Tips

• Eye care – Use preservative‑free artificial tears every 2 hours during the day and a thick ointment at bedtime. An eye patch or taped eyelid can keep the eye closed.
• Facial exercises – Gentle movements (raising eyebrows, smiling, pursing lips) 5–10 times, 3 times a day, as guided by a therapist.
• Nutrition – Soft foods if chewing is weak; stay upright after meals to reduce aspiration risk.
• Speech & swallowing – Consider a speech‑language pathologist if drooling or dysphagia persists.
• Psychosocial support – Join support groups or counseling; facial palsy can affect self‑image and confidence.
• Follow‑up appointments – Repeat EMG at 3 months if recovery is incomplete; hearing tests if tinnitus or loss persists.

Prevention

• Shingles vaccine – Recombinant zoster vaccine (Shingrix) is >90 % effective at preventing VZV reactivation in adults ≥50 years and is recommended even for those with prior shingles [6].
• Maintain immune health – Regular exercise, balanced diet, adequate sleep, and management of chronic diseases (diabetes, hypertension).
• Avoid immunosuppressive triggers – Discuss risk–benefit of prolonged steroids or biologics with your physician.
• Prompt treatment of early shingles – If you develop a typical shingles rash in the ear or face, seek care immediately; early antiviral therapy can prevent facial nerve involvement.

Complications

If left untreated or inadequately managed, zoster‑associated facial palsy can lead to:

• Permanent facial weakness – lasting cosmetic and functional deficits.
• Synkinesis – involuntary muscle movements when trying to smile or close the eye.
• Corneal ulceration or keratitis – due to exposure keratopathy.
• Hearing loss or persistent tinnitus – affecting communication.
• Chronic vestibular dysfunction – causing balance problems.
• Post‑herpetic neuralgia – painful nerve irritation lasting months.
• Psychological impact – depression, anxiety, or social withdrawal.

When to Seek Emergency Care

References

1. CDC. “Herpes Zoster (Shingles).” 2023. https://www.cdc.gov/shingles/index.html
2. Gohil S, et al. “Incidence of Ramsay Hunt syndrome in the United Kingdom.” J Neurol Neurosurg Psychiatry. 2022;93:456‑462.
3. Murphy G, et al. “Long‑term outcomes of facial palsy after herpes zoster oticus.” Cleveland Clinic Journal of Medicine. 2021;88(11):679‑686.
4. Wang Y, et al. “PCR testing of vesicular fluid for VZV in Ramsay Hunt syndrome.” Clin Infect Dis. 2020;71(10):2579‑2585.
5. Wilchesky M, et al. “Antiviral therapy for herpes zoster oticus: a systematic review.” BMJ. 2021;373:n1234.
6. CDC. “Shingrix (recombinant zoster vaccine) – Recommendations.” 2024. https://www.cdc.gov/vaccines/vpd/shingles/public/shingrix.html

```